GlassScriptPhysician profile
Allen L Beachy
NPI 1104853860
$20,562.70
in general payments reported to CMS, 2019-2025
56 companies · $1,144 in 2025
The $1,144 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,792 · 2020: $2,019 · 2021: $3,781 · 2022: $3,544 · 2023: $3,486 · 2024: $3,797 · 2025: $1,144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,427.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,645.08 | 2020-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $2,257.87 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,841.76 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $1,743.93 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,271.51 | 2019-2025 | |
| Amgen INC. | $1,262.04 | 2019-2025 | Evenity, Prolia, Repatha |
| Amarin Pharma, INC. | $998.99 | 2019-2022 | |
| Lilly USA, LLC | $814.96 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $705.05 | 2019-2025 | Jardiance |
| Allergan, INC. | $701.12 | 2019-2020 | |
| Astellas Pharma US INC | $500.49 | 2019-2024 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $494.93 | 2021-2025 | |
| Esperion Therapeutics, INC. | $492.06 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $460.91 | 2019-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $380.23 | 2019-2024 | Xarelto, Acclarent Navwire |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allen Beachy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.